Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Conbercept
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
China's Kanghong Pharma Hits Limit Down as France Stops Trials of Ophthalmic Drug
Details : No reasons for the suspension of project KHB-1802 were given nor was there any mention of whether it will be resumed in the near future nor whether it will affect the registration of the drug in France.
Product Name : Lumitin
Product Type : Protein
Upfront Cash : Inapplicable
March 29, 2021
Lead Product(s) : Conbercept
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Conbercept
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Conbercept is a new generation anti-VEGF fusion protein, approved and marketed in China as Lumitin®, for the treatment of retina diseases.
Product Name : Lumitin
Product Type : Protein
Upfront Cash : Inapplicable
December 23, 2020
Lead Product(s) : Conbercept
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
